Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 6, 2015, Pages 1273-1283

  Fox, Elizabeth ^a   Widemann, Brigitte C ^b   Pastakia, Devang ^c   Chen, Clara C ^d   Yang, Sherry X ^b   Cole, Diane ^b   Balis, Frank M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Multidrug resistance; P glycoprotein; Pediatric cancer; Pharmacokinetics; Phase I

Indexed keywords

DOCETAXEL; DOXORUBICIN; FILGRASTIM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; RAZOXANE; RHODAMINE; TARIQUIDAR; VINCRISTINE; ANTINEOPLASTIC AGENT; QUINOLINE DERIVATIVE; TAXOID; VINBLASTINE;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONSTIPATION; DESQUAMATION; DIARRHEA; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ESOPHAGITIS; EWING SARCOMA; FEMALE; FEVER; FLOW CYTOMETRY; HEPATOBLASTOMA; HODGKIN DISEASE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; LUNG BLASTOMA; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OSTEOSARCOMA; PAIN; PANCREATOBLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; RASH; RECOMMENDED DRUG DOSE; RHABDOMYOSARCOMA; SENSORY NEUROPATHY; SOLID TUMOR; SYNOVIAL CELL SARCOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESISTANCE; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; NEUTROPENIA; P-GLYCOPROTEINS; QUINOLINES; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; VOMITING;

EID: 84947564848     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2845-1     Document Type: Article

References (36)

1. Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G, Cantiello HF (1993) The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci U S A 90:312-316
2. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574-3582
3. Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC (2003) Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9:650-656
4. Arceci RJ (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-2222
5. Arceci RJ (2000) Can multidrug resistance mechanisms be modified? Br J Haematol 110:285-291
6. Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jager W, Haslacher H, Muller M, Langer O (2013) Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med 54:1181-1187
7. Bauer M, Zeitlinger M, Todorut D, Bohmdorfer M, Muller M, Langer O, Jager W (2013) Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology 91:12-19
8. Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM (1997) Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 15:1538-1543
9. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618
10. Bradshaw DM, Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16:3674-3690
11. Chan HS, Grogan TM, DeBoer G, Haddad G, Gallie BL, Ling V (1996) Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur J Cancer 32A:1051-1061
12. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114
13. Deuchars KL, Ling V (1989) P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 16:156-165
14. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84:265-269
15. Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22:7512-7523
16. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Lonnerholm G (2002) Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol 38:329-337
17. Gardner ER, Smith NF, Figg WD, Sparreboom A (2009) Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 28:99
18. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
19. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T (2006) Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. Clin Cancer Res 12:516-522
20. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569-580
21. Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, Fricker G, Konig B, Buschauer A (2009) Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 52:1190-1197
22. Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-229
23. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403-411
24. Montesinos RN, Moulari B, Gromand J, Beduneau A, Lamprecht A, Pellequer Y (2014) Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab Dispos 42:700-706
25. Pajeva IK, Sterz K, Christlieb M, Steggemann K, Marighetti F, Wiese M (2013) Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein. ChemMedChem 10:1701-1713
26. Pick A, Klinkhammer W, Wiese M (2010) Specific inhibitors of the breast cancer resistance protein (BCRP). ChemMedChem 5:1498-1505
27. Pinwnica-Worms D (2000) Functional identification of multidrug resistance gene expression in vivo. Lippincott Williams & Wilkins, New Orleans
28. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682-691
29. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96:3900-3905
30. Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S (1999) Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93:306-314
31. Seibel NL, Blaney SM, O'Brien M, Krailo M, Hutchinson R, Mosher RB, Balis FM, Reaman GH (1999) Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 5:733-737
32. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191
33. Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL (2009) Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol 64:243-251
34. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2:7-12
35. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL (2000) MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685-2694
36. Zinzi L, Capparelli E, Cantore M, Contino M, Leopoldo M, Colabufo NA (2014) Small and innovative molecules as new strategy to revert MDR. Front Oncol 4:2